Researchers Identify Epigenomic Test That Could Improve Treatment For Specific Gastric Cancers

New information on stomach cancer from the John Wayne Cancer Institute...they also have a lot going on with breast cancer research studies and clinical trials...BD

A study by researchers at the John Wayne Cancer Institute at Saint John's Health Center in a recent issue of Journal of Clinical Oncology identifies activation of the enzyme COX-2 in gastric cancer tumors as a prognostic indicator for poor outcome. The study suggests that inhibiting COX-2 with readily available drugs may improve outcomes for some gastric cancer patients.
Hoon noted that COX-2 remains a significant research interest for all gastrointestinal cancers, and that previous studies have suggested COX-2 inhibition can play a role in colon cancer prevention. The current study, which continues a strong collaboration between JWCI and the Dutch Gastric Cancer Group at Leiden, is one of the largest biomarker studies to date relating COX-2 and gastric cancer. "It is the first to suggest an epigenetic biomarker for gastric cancer progression," he added.
Celebrating over 25 years, the John Wayne Cancer Insitute (JWCI) has become one of the premier cancer research and treatment centers in the nation. Discoveries made by the research team at JWCI have international impact. Our scientists work closely with all institute departments to ensure research is being supported in the highest manner possible. Through collaboration with scientists across the nation as well as participation in international conferences and symposiums, JWCI researchers stay at the forefront of international cancer research.